

Client: ARUP Example Report Only  
500 Chipeta Way  
Salt Lake City, UT 84108  
UNITED STATES

Physician: TEST,

**Patient: ARUPTEST, LUPUS RFLX  
ABNORMAL**

**DOB:** 5/17/1948  
**Sex:** Male  
**Patient Identifiers:** 55416  
**Visit Number (FIN):** 55804  
**Collection Date:** 12/15/2023 07:00

**Lupus Anticoagulant Reflex Panel**

ARUP test code 3017009

Prothrombin Time (PT)	15.0 s		(Ref Interval: 12.0-15.5)
PTT-LA Ratio	<b>1.88</b>	<b>H</b>	(Ref Interval: <=1.20)
dRVVT Screen Ratio	<b>2.08</b>	<b>H</b>	(Ref Interval: <=1.20)
Anti-Xa Qualitative Interpretation	Present		(Ref Interval: Not Present)
Thrombin Time (TT)	19.5 s		(Ref Interval: <=19.5)
Anticoagulant Medication Neutralization	DOAC-Stop		(Ref Interval: Not Performed)
Neutralized PTT-LA Ratio	<b>1.25</b>	<b>H</b>	(Ref Interval: <=1.20)
Neutralized dRVVT Screen Ratio	<b>1.68</b>	<b>H</b>	(Ref Interval: <=1.20)
dRVVT 1:1 Mix Ratio	<b>1.27</b>	<b>H</b>	(Ref Interval: <=1.20)
dRVVT Confirmation Ratio	<b>1.22</b>	<b>H</b>	(Ref Interval: <=1.20)
Hexagonal Phospholipid Confirmation	<b>13.8 s</b>	<b>H</b>	(Ref Interval: <=7.9)
Lupus Anticoagulant, Interpretation	See Note		

Lupus anticoagulant detected in a sample treated to remove anticoagulant medications.

This panel detected evidence for an anticoagulant medication (heparin, direct thrombin inhibitor, or direct Xa inhibitor) and drug neutralization was performed. Presence of these anticoagulant medications in concentrations exceeding the capacity of the neutralizing reagent, or presence of warfarin effect, may still result in interference in lupus anticoagulant assays. Lupus anticoagulant testing is optimally performed in the absence of anticoagulant medications to avoid erroneous results (J Thromb Haemost. 2020; 18:1569-1575).

Testing on two or more occasions at least 12 weeks apart is recommended to confirm persistently positive results (J Thromb Haemost. 2020; 18:2828-2839). Lupus anticoagulant testing is best performed when the patient is not acutely ill and not anticoagulated since acute inflammation or high concentrations

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: ARUPTEST, LUPUS RFLX ABNORMAL  
ARUP Accession: 23-349-100521  
Patient Identifiers: 55416  
Visit Number (FIN): 55804  
Page 1 of 2 | Printed: 12/20/2023 6:16:20 AM

of anticoagulant medications may lead to erroneous results. Consider testing for cardiolipin and beta-2 glycoprotein 1 antibodies (IgG and IgM) if this testing has not already been performed.

Current guidelines vary regarding use of mixing studies for lupus anticoagulant identification. The interpretation of "lupus anticoagulant detected" was generated due to a prolonged aPTT and/or DRVVT that demonstrated phospholipid dependence in the confirmatory assay(s). Multiple or severe factor deficiencies (including warfarin therapy) and specific factor inhibitors may result in false positive results in lupus anticoagulant assays. If clinically indicated, consider performing factor assays and/or specific factor inhibitor assays for further evaluation.

**INTERPRETIVE INFORMATION: Lupus Anticoagulant Reflex Panel**

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**VERIFIED/REPORTED DATES**

Procedure	Accession	Collected	Received	Verified/Reported
Prothrombin Time (PT)	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
PTT-LA Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
dRVVT Screen Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Anti-Xa Qualitative Interpretation	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Thrombin Time (TT)	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Anticoagulant Medication Neutralization	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Neutralized PTT-LA Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Neutralized dRVVT Screen Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
dRVVT 1:1 Mix Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
dRVVT Confirmation Ratio	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Hexagonal Phospholipid Confirmation	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM
Lupus Anticoagulant, Interpretation	23-349-100521	12/15/2023 7:00:00 AM	12/15/2023 7:01:11 AM	12/19/2023 10:39:00 AM

**END OF CHART**

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: ARUPTEST, LUPUS RFLX ABNORMAL  
ARUP Accession: 23-349-100521  
Patient Identifiers: 55416  
Visit Number (FIN): 55804  
Page 2 of 2 | Printed: 12/20/2023 6:16:20 AM